mhurhangee/ep-ind-claims huggingface dataset:
Process for the preparation of complexes of iron hydroxide and activated glucose syrup, wherein the molecular weight of the complex is in the range of from 100 kDa to 150 kDa, as measured by high performance liquid chromatography-gel permeation chromatography (HPLC-GPC), said process comprising the steps: (i) providing an aqueous solution of glucose syrup, having a dextrose equivalent of at least 21 and at most 60, as determined by gravimetrical analysis, at a temperature in the range of from 25°C to 80°C and at a pH in the range of from 6 to 13; (ii) adding hydrogen peroxide, and optionally a catalytic amount of an oxidation catalyst, to the solution of (i), while maintaining the pH and temperature within the range as defined in step (i), allowing the solution to cool down to a temperature in the range of from 10°C to 45°C, keeping the solution at this temperature for 5 min to 24 hours, thereby obtaining the activated glucose syrup; (iii) converting said activated glucose syrup into a complex with iron hydroxide; and (iv) obtaining a complex of iron hydroxide and activated glucose syrup, wherein the hydrogen peroxide is used in a total amount of 0.0005-0.01 mol/g (glucose syrup) multiplied with the correction factor: (dextrose equivalent of the glucose syrup)/21, wherein the complex has an iron content in the range of from 27 to 35 wt.%, based on the weight of the complex; and wherein the obtained complex of iron hydroxide and activated glucose syrup has more than two -COOH groups per glucose molecule and wherein the glucose syrup of step (i) does not have any - COOH group at the glucose molecule. (i) providing an aqueous solution of glucose syrup, having a dextrose equivalent of at least 21 and at most 60, as determined by gravimetrical analysis, at a temperature in the range of from 25°C to 80°C and at a pH in the range of from 6 to 13; (ii) adding hydrogen peroxide, and optionally a catalytic amount of an oxidation catalyst, to the solution of (i), while maintaining the pH and temperature within the range as defined in step (i), allowing the solution to cool down to a temperature in the range of from 10°C to 45°C, keeping the solution at this temperature for 5 min to 24 hours, thereby obtaining the activated glucose syrup; (iii) converting said activated glucose syrup into a complex with iron hydroxide; and (iv) obtaining a complex of iron hydroxide and activated glucose syrup, wherein the hydrogen peroxide is used in a total amount of 0.0005-0.01 mol/g (glucose syrup) multiplied with the correction factor: (dextrose equivalent of the glucose syrup)/21, wherein the complex has an iron content in the range of from 27 to 35 wt.%, based on the weight of the complex; and wherein the obtained complex of iron hydroxide and activated glucose syrup has more than two -COOH groups per glucose molecule and wherein the glucose syrup of step (i) does not have any - COOH group at the glucose molecule.
An orthopaedic glenoid prosthesis for implantation into a glenoid surface of a scapula so as to provide a bearing surface for a natural or prosthetic head of a humerus, the glenoid prosthesis comprising: a metallic defect-filling component (60;160;260) sized and shaped to fit and be implanted within a defect in the glenoid surface, the metallic defect-filling component comprising a body with a lateral surface (64b; 164b) that forms an attachment or restructured surface and having (i) a first hole positioned in the centre of the metallic defect-filling component, and (ii) a second hole positioned between the centre and an edge of the metallic defect-filling component; and a polymer glenoid component secured to the metallic defect-filling component, the polymer glenoid component being discrete from the metallic defect-filling component and having (i) a bearing surface configured to articulate with the head of the humerus, and (ii) an engaging surface that is opposite the bearing surface, the engaging surface comprising (a) an anchor peg positioned in a centre of the polymer glenoid component and extending into the first hole of the metallic defect-filling component so as to secure the polymer glenoid component to the metallic defect-filling component, and (b) a stabilizing peg positioned between the centre and an edge of the polymer glenoid component and extending into the second hole of the metallic defect-filling component to prevent rotation of the polymer glenoid component, characterised in that the metallic defect-filling component comprises a body with a medial surface (64a; 164a) that is adapted to contact the inner surface of the defect. a metallic defect-filling component (60;160;260) sized and shaped to fit and be implanted within a defect in the glenoid surface, the metallic defect-filling component comprising a body with a lateral surface (64b; 164b) that forms an attachment or restructured surface and having (i) a first hole positioned in the centre of the metallic defect-filling component, and (ii) a second hole positioned between the centre and an edge of the metallic defect-filling component; and a polymer glenoid component secured to the metallic defect-filling component, the polymer glenoid component being discrete from the metallic defect-filling component and having (i) a bearing surface configured to articulate with the head of the humerus, and (ii) an engaging surface that is opposite the bearing surface, the engaging surface comprising (a) an anchor peg positioned in a centre of the polymer glenoid component and extending into the first hole of the metallic defect-filling component so as to secure the polymer glenoid component to the metallic defect-filling component, and (b) a stabilizing peg positioned between the centre and an edge of the polymer glenoid component and extending into the second hole of the metallic defect-filling component to prevent rotation of the polymer glenoid component,
A composition comprising a CD19xCD3 bispecific antibody for use in a method for the treatment of tumorous mass of lymph node tissue and/or extranodal lymphoma caused by diffuse large B cell lymphoma (DLBCL) in a patient who is refractory to chemotherapy treatment and/or in relapse after treatment with chemotherapy, wherein the composition is administered in combination with a glucocorticoid.
An electrical stimulation apparatus comprising: a frame worn on a user; an electrode module including a plurality of microelectrodes, wherein one surface of the electrode module is connected to the frame; and a processor configured to control an operation of the electrode module such that a target effect is capable of being provided to the user through electrical stimulation in a state where the frame is worn on the user, wherein the electrical stimulation apparatus further comprises a single patch covering the plurality of microelectrodes, and wherein the other surface of the electrode module face the user while being covered by the single patch. a frame worn on a user; an electrode module including a plurality of microelectrodes, wherein one surface of the electrode module is connected to the frame; and a processor configured to control an operation of the electrode module such that a target effect is capable of being provided to the user through electrical stimulation in a state where the frame is worn on the user, wherein the electrical stimulation apparatus further comprises a single patch covering the plurality of microelectrodes, and wherein the other surface of the electrode module face the user while being covered by the single patch.
A vaccine for use in a method for vaccinating a dog for the following canine diseases: 1) infectious canine hepatitis caused by CAV-1; 2) canine distemper caused by canine distemper virus; and 3) canine parvoviral enteritis caused by canine parvovirus; wherein the vaccine comprises the following modified live viruses: 1) canine adenovirus type 2 (CAV-2); 2) canine distemper virus; and 3) canine parvovirus; characterized in that the vaccine is administered subcutaneously in a first dose, orally in a second dose administered from 7 to 35 days inclusive after the first dose, orally in an optional third dose administered from 7 to 35 days inclusive after the second dose, and orally in one or more annual doses, one year after the first dose or from four weeks before to four weeks after the one year anniversary of the first dose.
A method for starting up a combined cycle plant including a gas turbine configured to be driven by fuel supply, a waste heat recovery boiler configured to generate steam by using heat from exhaust gas exhausted from the gas turbine, a steam turbine configured to be driven by the steam from the waste heat recovery boiler, a condenser configured to return the steam exhausted from the steam turbine to water, and a generator configured to generate electricity by drive of the steam turbine, the method comprising: a gas turbine start-up step (S11Q) of increasing an output of the gas turbine to a rated output by supplying fuel to the gas turbine; a steam admission step of, when a temperature of the steam from the waste heat recovery boiler reaches or exceeds a predetermined temperature, starting steam supply to the steam turbine; a synchronization step of, after the steam admission step, when a rotational speed of the steam turbine reaches a rated rotational speed, synchronizing the generator to a power system; an ST generator output control step of, after the generator is synchronized, controlling a flow rate of the steam flowing into the steam turbine so that an output of the generator increases according to a target output change pattern; and a thermal stress estimation step of estimating a thermal stress generated in the steam turbine based on a temperature of the steam flowing into the steam turbine, wherein in the ST generator output control step, when the thermal stress estimated in the thermal stress estimation step reaches or exceeds a predetermined first thermal stress, the flow rate of the steam flowing into the steam turbine is controlled so that a change in the output of the generator is smaller than a change indicated by the target output change pattern. a gas turbine start-up step (S11Q) of increasing an output of the gas turbine to a rated output by supplying fuel to the gas turbine; a steam admission step of, when a temperature of the steam from the waste heat recovery boiler reaches or exceeds a predetermined temperature, starting steam supply to the steam turbine; a synchronization step of, after the steam admission step, when a rotational speed of the steam turbine reaches a rated rotational speed, synchronizing the generator to a power system; an ST generator output control step of, after the generator is synchronized, controlling a flow rate of the steam flowing into the steam turbine so that an output of the generator increases according to a target output change pattern; and a thermal stress estimation step of estimating a thermal stress generated in the steam turbine based on a temperature of the steam flowing into the steam turbine, wherein in the ST generator output control step, when the thermal stress estimated in the thermal stress estimation step reaches or exceeds a predetermined first thermal stress, the flow rate of the steam flowing into the steam turbine is controlled so that a change in the output of the generator is smaller than a change indicated by the target output change pattern.
Composition comprising, as an active substance, a mixture of the following compounds: -non-2-enal, of the following formula I: nonanoic acid, of the following formula II: octanal, of the following formula III: nonanal, of the following formula IV: and oct-1-en-3-ol, of the following formula V: -non-2-enal, of the following formula I: nonanoic acid, of the following formula II: octanal, of the following formula III: nonanal, of the following formula IV: and oct-1-en-3-ol, of the following formula V:
A human proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, wherein said PCSK9 inhibitor is an antibody or antigen-binding fragment thereof which specifically binds PCSK9 and comprises the heavy chain variable region (HCVR) amino acid sequence set forth in SEQ ID NO: 1, and the light chain variable region (LCVR) amino acid sequence set forth in SEQ ID NO: 6, for use in the treatment of hypercholesterolemia in a high cardiovascular risk patient who has: (a) a serum low-density lipoprotein cholesterol (LDL-C) level above 70 mg/dL despite taking a stable daily maximally tolerated dose of statin therapy for at least 4 weeks; and (b) established coronary heart disease or CHD risk equivalents, the equivalents being defined by including one or more of the following four criteria: 1) peripheral arterial disease; 2) ischemic stroke; 3) chronic kidney disease; and/or 4) a history of diabetes mellitus and 2 or more additional risk factors selected from the group consisting of: a) history of hypertension, b) history of ankle-brachial index ≤0.90, c) history of microalbuminuria or macroalbuminuria or dipstick urinalysis at screening visit with >2+ protein, d) history of preproliferative or proliferative retinopathy or laser treatment for retinopathy, and e) known family history of premature CHD. (a) a serum low-density lipoprotein cholesterol (LDL-C) level above 70 mg/dL despite taking a stable daily maximally tolerated dose of statin therapy for at least 4 weeks; and (b) established coronary heart disease or CHD risk equivalents, the equivalents being defined by including one or more of the following four criteria: 1) peripheral arterial disease; 2) ischemic stroke; 3) chronic kidney disease; and/or 4) a history of diabetes mellitus and 2 or more additional risk factors selected from the group consisting of: a) history of hypertension, b) history of ankle-brachial index ≤0.90, c) history of microalbuminuria or macroalbuminuria or dipstick urinalysis at screening visit with >2+ protein, d) history of preproliferative or proliferative retinopathy or laser treatment for retinopathy, and e) known family history of premature CHD.
Safety architecture for at least two batteries, wherein each battery comprises at least one respective electrochemical cell, and wherein the at least two batteries are each combined with at least one data processing unit to form a respective module (202, 204), wherein the safety architecture is set up such that the at least one data processing unit of at least one first module (202, 204) processes input signals for at least one second module (204, 202), wherein a shutdown path for the at least one second module (204, 202) can be activated by output signals from the at least one first module (202, 204).
Textile machine with several spinning places, whereby each spinning place comprises a can feeding means, a spinning unit, and a winding up unit, the spinning unit and the winding up unit are modular structured and exchangeable, characterized in that the spinning unit and the winding up unit are attached in or on the machine frame and are each driven by their own motors (12, 13) and for this comprises at least one own drive means, preferably a reluctance motor.
An apparatus for liquid transfer imprint lithography using a roll stamp, comprising a roll unit having a roll rotating part rotating a roll stamp with a constant velocity, a plane unit disposed under the roll unit, and a control unit controlling an operation of the roll unit and the plane unit, wherein the roll unit further comprises a roll stamp, a horizontal moving stage and a roll angular compensating stage, the roll stamp having a hollow cylindrical shape, having a hardening or curing element inside the roll stamp and having a pattern formed on an outer surface of the roll stamp, the horizontal moving stage moving the roll stamp along an X axis, the roll angular compensating stage adjusting an angle of the roll stamp wherein the plane unit comprises a first substrate, a first fixing chuck, a first substrate driving part, a second substrate, a second fixing chuck and a second substrate driving part, a flat resist being coated on the first substrate, the first fixing chuck being disposed over a table and the first substrate being fixed at the first fixing chuck, the first substrate driving part vertically moving the first fixing chuck along a Z axis, the second substrate being spaced apart from the first substrate and being arranged with the first substrate in parallel, the second fixing chuck being disposed over the table and the second substrate being fixed to the second fixing chuck, the second substrate driving part adapted to be independently driven from the first substrate driving part and vertically moving the second fixing chuck along the Z axis, wherein the control unit controls the operation such that the roll stamp and the first substrate makes contact with each other and are pressed with each other so that the resist attached to the surface of the roll stamp is re-transferred to the second substrate.
A refrigerating oil composition comprising: a refrigerant containing 50 mass% or more of a C1-C8 hydrocarbon compound; and a base oil comprising a polyvinyl ether represented by formula: wherein each of R 3 and R 4 represents a hydrogen atom, a C1-C18 hydrocarbon group or a C2-C18 acyl group; R 5 represents a C1-C4 hydrocarbon group; R 6 represents a C2-C4 hydrocarbon group, provided that the number of carbon atoms contained in R 6 is greater than the number of carbon atoms contained in R 5; p is an integer of 1 or more; and q is an integer of 1 or more; wherein the following conditions are satisfied: (i) the solubility of the refrigerant in the base oil is 40 mass% or less at 40°C and 1.2 MPa, and (ii) the mixture viscosity of the refrigerating oil composition is 0.1 mm 2 /s or more at 90°C and 2.3 MPa. a refrigerant containing 50 mass% or more of a C1-C8 hydrocarbon compound; and a base oil comprising a polyvinyl ether represented by formula: wherein each of R 3 and R 4 represents a hydrogen atom, a C1-C18 hydrocarbon group or a C2-C18 acyl group; R 5 represents a C1-C4 hydrocarbon group; R 6 represents a C2-C4 hydrocarbon group, provided that the number of carbon atoms contained in R 6 is greater than the number of carbon atoms contained in R 5; p is an integer of 1 or more; and q is an integer of 1 or more; wherein the following conditions are satisfied: (i) the solubility of the refrigerant in the base oil is 40 mass% or less at 40°C and 1.2 MPa, and (ii) the mixture viscosity of the refrigerating oil composition is 0.1 mm 2 /s or more at 90°C and 2.3 MPa. wherein each of R 3 and R 4 represents a hydrogen atom, a C1-C18 hydrocarbon group or a C2-C18 acyl group; R 5 represents a C1-C4 hydrocarbon group; R 6 represents a C2-C4 hydrocarbon group, provided that the number of carbon atoms contained in R 6 is greater than the number of carbon atoms contained in R 5; p is an integer of 1 or more; and q is an integer of 1 or more; wherein the following conditions are satisfied: (i) the solubility of the refrigerant in the base oil is 40 mass% or less at 40°C and 1.2 MPa, and (ii) the mixture viscosity of the refrigerating oil composition is 0.1 mm 2 /s or more at 90°C and 2.3 MPa. (i) the solubility of the refrigerant in the base oil is 40 mass% or less at 40°C and 1.2 MPa, and (ii) the mixture viscosity of the refrigerating oil composition is 0.1 mm 2 /s or more at 90°C and 2.3 MPa.
A method for wireless communication, comprising: receiving, by a radio access network, RAN, device (205; 405; 505; 905; 1005; 1105) of a wireless communication system, an indication of a traffic flow to be served by the wireless communication system; determining, by the RAN device, time offset information for transmissions of the traffic flow based at least in part on the indication; and transmitting, by the RAN device to at least one application entity in the wireless communication system, the time offset information in response to the indication, wherein the at least one application entity includes an Application Function, AF, on an edge server (245; 445; 545) and/or an application on a user device (215; 310, 315; 415; 515); and wherein the time offset is based on a common clock shared between nodes (405, 415, 445) communicating the traffic flow or based on packet arrivals of one or more existing traffic flows. receiving, by a radio access network, RAN, device (205; 405; 505; 905; 1005; 1105) of a wireless communication system, an indication of a traffic flow to be served by the wireless communication system; determining, by the RAN device, time offset information for transmissions of the traffic flow based at least in part on the indication; and transmitting, by the RAN device to at least one application entity in the wireless communication system, the time offset information in response to the indication, wherein the at least one application entity includes an Application Function, AF, on an edge server (245; 445; 545) and/or an application on a user device (215; 310, 315; 415; 515); and wherein the time offset is based on a common clock shared between nodes (405, 415, 445) communicating the traffic flow or based on packet arrivals of one or more existing traffic flows.
A solid oxide fuel cell comprising a solid electrolyte layer, a cathode layer which is formed on one surface of the solid electrolyte layer and which contains at least Sr, an anode layer which is formed on the other surface of the solid electrolyte layer, and an intermediate layer formed between the solid electrolyte layer and the cathode layer,wherein at least a part of the intermediate layer is an element diffusion prevention layer; the element diffusion prevention layer is formed of a complex oxide containing at least one rare earth element and Zr; wherein after the solid oxide fuel cell has been subjected to an heating in air in an electric furnace from room temperature to 1,000°C at an temperature elevation rate of 4 °C/s and maintained at 1,000°C for 100 hr, the element diffusion prevention layer has a thickness of 600 nm or more to 2,000 nm or less and an Sr coverage of 90% or lower, and has an average grain size of 0.5 μm or more to 0.71 μm or less. a solid electrolyte layer, a cathode layer which is formed on one surface of the solid electrolyte layer and which contains at least Sr, an anode layer which is formed on the other surface of the solid electrolyte layer, and an intermediate layer formed between the solid electrolyte layer and the cathode layer,wherein at least a part of the intermediate layer is an element diffusion prevention layer; the element diffusion prevention layer is formed of a complex oxide containing at least one rare earth element and Zr; wherein after the solid oxide fuel cell has been subjected to an heating in air in an electric furnace from room temperature to 1,000°C at an temperature elevation rate of 4 °C/s and maintained at 1,000°C for 100 hr, the element diffusion prevention layer has a thickness of 600 nm or more to 2,000 nm or less and an Sr coverage of 90% or lower, and has an average grain size of 0.5 μm or more to 0.71 μm or less.